AltruBio is developing first-in-class immune-modulators targeting diseases of #immunology and #inflammation. Its world-class global team brings a breadth of expertise in immunology and drug development that will help advance their biologic treatments to patients. Learn more at https://www.altrubio.com/altrubio/en

AltruBio Inc.

Following the close of our Series B fundraising, our President and Chief Executive Officer, Dr. Judy Chou and our Senior Director of Business Development, Edwin Powers are engaging with biotech and pharma leaders across the industry at #BIO2024, building the excitement for our Phase 2 trials in UC and the promising future of next-generation therapies in the I&I space.

The novel immune checkpoint enhancer (ICE) ALTB-268 invented at AltruBio Inc.  has the unique mechanism of action to be potentially more effective and durable. With our recently closed fundraising, we are excited to move forward with our phase 2 program in ulcerative colitis. Read more about AltruBio’s progress in the STAT article here: https://bit.ly/4bX4BeC
#immunecheckpointenhancer #ulcerativecolitis #IBD

We are grateful to receive the biggest raise of the week in biotech industry to accelerate our phase 2 program in order to help patients suffering from ulcerative colitis. https://lnkd.in/gBsmNMBG
#ibd #ulcerativecolitis #immunecheckpointenhancer

Thank you to the New York Stock Exchange NYSE for celebrating our Series B on the historic trading floor! What a surprise!

With over three million individuals in the United States living with ulcerative colitis (UC) and Crohn's disease, there is a clear and urgent unmet medical need. We value the widespread recognition of AltruBio’s oversubscribed Series B raise as we are accelerating our efforts to advance our clinical studies in UC. Check out this article in The Wall Street Journal: https://on.wsj.com/4axd6Mn

Thank you Nasdaq for the surprising congratulations at Times Square today!

TRON is a competitor of AltruBio in the field of biotech, immune system regulation, and novel therapeutics. They focus on cancer and immune-related inflammatory diseases.

TRON

HUYA Bioscience International is a competitor of AltruBio in the field of biologic treatments and novel therapeutics. They also focus on cancer and immune-related inflammatory diseases.

HUYA Bioscience International

Kyowa Kirin is a main competitor of AltruBio. They are known for their work in the biopharmaceutical industry, particularly in the field of oncology and immunotherapy.

Kyowa Kirin

Takeda is a main competitor of AltruBio in the biopharmaceutical industry. They have a strong focus on developing therapies for various diseases, including oncology and immunotherapy.

Takeda

Biocon is a main competitor of AltruBio in the biotechnology and biopharmaceutical industry. They are known for their work in developing biologic treatments and novel therapeutics for various diseases.

Biocon

Shanghai Junshi Biosciences is a main competitor of AltruBio in the biotechnology and biopharmaceutical industry. They focus on developing novel therapies for various diseases, including oncology and immunotherapy.

Shanghai Junshi Biosciences

Oncosec Medical is a developer in the field of new approaches and alternatives in the IO combo space, making them a competitor of AltruBio in the immuno-oncology field.

Oncosec Medical

Heat Biologics is a developer that exemplifies new approaches and alternatives in the IO combo space, making them a competitor of AltruBio in the immuno-oncology field.

Heat Biologics

Cellectar Biosciences is a top competitor of AltruBio. They are known for their work in developing novel cancer-targeted therapeutics, making them a direct competitor in the oncology space.

Cellectar Biosciences

Actinium Pharmaceuticals is a top competitor of AltruBio. They focus on developing targeted radioimmunotherapies for cancer, positioning them as a direct competitor in the oncology space.

Actinium Pharmaceuticals

AltruBio is a clinical-stage biotechnology company focused on discovering and developing novel therapies for the treatment of various diseases, including colorectal cancer. The company leverages its proprietary technology platform to create immunotherapies aimed at harnessing the body's immune system to fight cancer and other diseases.

AltruBio

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

news impact assignment basic	general
public peers	general	Jun 22, 2024 4:34 AM	57560cc9
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jun 22, 2024 6:01 AM	eb3013ab
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jun 22, 2024 4:34 AM	ade45b2e
translate crunchbase fundingrounds	general
peers	general
news basic	general	Jun 22, 2024 4:34 AM	fd9fdff5
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:ALTRUBIO

AltruBio